The DEBBRAH phase II study demonstrated the feasibility of combining intracranial treatment with T-Dxd and radiation, showing manageable toxicity in patients with HER2-positive and HER2-low breast cancer who underwent whole-brain radiation therapy and/or SRS. Here, ERBB2 is linked to breast cancer.